The emergence of PD-(L1) treatments has provided patients options where previously none existed, and the leading forms of these therapies have gone on to blockbuster sales.
Dr Prasanth Reddy, head of oncology at Labcorp, tells us how the company works with cancer care teams, biopharma partners, and patients as an integral part of the patient journey from testi
Ben Hargreaves examines what advantages radiopharmaceuticals offer in the treatment of cancer and why there has been interest from big pharma in developing these types of therapies.
